Cardio-oncology: management of cardiovascular toxicity

Markman, Timothy M.; Markman, Maurie

doi:10.12688/f1000research.14542.1

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mainstays of therapy are angiotensin-converting enzyme (ACE) inhibitors and β-blockers, up-titrated to the maximum tolerated doses, with diuretics, when needed. 67 Lifestyle modifications (healthy diet, smoking cessation, regular exercise, and weight control) should be strongly advised. In particular, aerobic exercise (walking and cycling activities) is considered a promising nonpharmacological strategy to prevent and/or treat chemotherapy-induced cardiotoxicity.…”

Section: Arrhythmias and Atrial Fibrillationmentioning

confidence: 99%

The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology

Tufano

Coppola

Galderisi

2021

Semin Thromb Hemost

View full text Add to dashboard Cite

Progress in the treatment of cancer has significantly improved survival of oncologic patients in recent decades. However, anticancer therapies, particularly some new, more potent and targeted agents, are potentially cardiotoxic. As a consequence, cardiovascular complications, including heart failure, arterial hypertension, coronary artery disease, venous thromboembolism, peripheral vascular disease, arrhythmias, pericardial disease, and pulmonary hypertension, as related to cancer itself or to anticancer treatments, are increasingly observed and may adversely affect prognosis in oncologic patients. Cardiovascular oncology is an emerging field in cardiology and internal medicine, which is rapidly growing, dealing with the prevention, the early detection, and the management of cardiovascular disease, in all stages of anticancer therapy and during the survivorship period, now crucial for reducing cardiovascular morbidity and mortality in cancer patients. In this narrative review, the existing literature regarding the epidemiology of cardiovascular oncology, the mechanisms of cardiovascular complications in cancer, and the pathophysiology of cardiotoxicity related to chemotherapeutic agents, targeted therapies, immunotherapies, and radiotherapy will be analyzed and summarized.

show abstract

Section: Arrhythmias and Atrial Fibrillationmentioning

confidence: 99%

The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology

Tufano

Coppola

Galderisi

2021

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

Sunder

Sharma

Pokharel

2023

Sig Transduct Target Ther

106

View full text Add to dashboard Cite

Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown significant utility in the treatment of multiple hematological malignancies and solid tumors, including chronic myelogenous leukemia, non-small cell lung cancers, gastrointestinal stromal tumors, and HER2-positive breast cancers. Given their widespread applications, an increasing frequency of TKI-induced adverse effects has been reported. Although TKIs are known to affect multiple organs in the body including the lungs, liver, gastrointestinal tract, kidneys, thyroid, blood, and skin, cardiac involvement accounts for some of the most serious complications. The most frequently reported cardiovascular side effects range from hypertension, atrial fibrillation, reduced cardiac function, and heart failure to sudden death. The potential mechanisms of these side effects are unclear, leading to critical knowledge gaps in the development of effective therapy and treatment guidelines. There are limited data to infer the best clinical approaches for the early detection and therapeutic modulation of TKI-induced side effects, and universal consensus regarding various management guidelines is yet to be reached. In this state-of-the-art review, we examine multiple pre-clinical and clinical studies and curate evidence on the pathophysiology, mechanisms, and clinical management of these adverse reactions. We expect that this review will provide researchers and allied healthcare providers with the most up-to-date information on the pathophysiology, natural history, risk stratification, and management of emerging TKI-induced side effects in cancer patients.

show abstract

Cardio-oncology: management of cardiovascular toxicity

Cited by 2 publications

References 37 publications

The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology

The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

Contact Info

Product

Resources

About